The hemodynamic flow alteration devices market size has grown strongly in recent years. It will grow from $0.88 billion in 2025 to $0.96 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to rising prevalence of cardiovascular disorders, increasing volume of vascular intervention procedures, advancements in catheter-based technologies, wider availability of specialized interventional devices, improved clinical outcomes in flow management.
The hemodynamic flow alteration devices market size is expected to see strong growth in the next few years. It will grow to $1.3 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing adoption of precision medicine in vascular care, rising demand for minimally invasive cardiac procedures, expansion of neurovascular intervention capabilities, growing investment in advanced interventional cardiology devices, increasing focus on reducing procedural complications. Major trends in the forecast period include increasing adoption of advanced embolic protection technologies, rising use of minimally invasive flow alteration devices, growing integration of precision-guided cto devices, expansion of procedure-specific device designs, enhanced focus on patient-specific hemodynamic optimization.
The rising prevalence of cardiovascular diseases is expected to drive growth in the hemodynamic flow alteration devices market in the coming years. Cardiovascular disease (CVD) is a broad category of conditions affecting the heart and blood vessels. The increase in CVD prevalence is fueled by factors such as aging populations, poor dietary habits, sedentary lifestyles, and rising rates of conditions like hypertension and diabetes. Hemodynamic flow alteration devices are increasingly needed to manage and improve blood flow in patients with heart failure, hypertension, and arterial blockages. For example, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million individuals in the UK are currently affected by heart and circulatory diseases - 4 million men and 3.6 million women. This number is projected to rise by 1 million by 2030 and by 2 million more than current figures by 2040. Therefore, the growing prevalence of cardiovascular disease is driving the hemodynamic flow alteration devices market.
Major players in the hemodynamic flow alteration devices market are emphasizing technological innovations, such as hybrid polymer-metal flow-diverting stents, to enhance the safety, efficacy, and long-term outcomes of neurovascular interventions. Hybrid polymer-metal flow-diverting stents combine the mechanical strength of metal with the flexibility and biocompatibility of polymer, allowing controlled hemodynamic flow alteration, reduced thrombogenicity, and improved vessel healing in patients with brain aneurysms. For example, in June 2023, Fluid Biomed Inc., a Canada-based medical device company, launched REDIRECT, its first-in-human clinical trial, successfully implanting ReSolv, the world’s first hybrid polymer-metal neurovascular stent. The Phase 1 study demonstrated safe implantation with no adverse events at the 30-day follow-up, marking a milestone in brain aneurysm treatment by integrating advanced materials engineering with minimally invasive neurovascular therapy to improve patient outcomes.
In October 2024, Johnson & Johnson, a pharmaceutical company based in the US, acquired V-Wave Inc. for an undisclosed sum. This acquisition is intended to bolster Johnson & Johnson's position in the cardiovascular disease sector by adding V-Wave's groundbreaking Ventura interatrial shunt to its MedTech portfolio. V-Wave Inc., a US-based company, specializes in the development of hemodynamic flow alteration devices.
Major companies operating in the hemodynamic flow alteration devices market are Cardinal Health Inc., Abbott Laboratories, Medtronic plc, Siemens Healthcare GmbH, Becton Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., ZOLL Medical Corporation, Getinge AB, Lepu Medical Technology (Beijing) Co. Ltd., Abiomed Inc., LivaNova PLC, Cordis US Corp., Silk Road Medical Inc., Berlin Heart GmbH, CorWave SA, Jarvik Heart Inc., CARMAT SA.
North America was the largest region in the hemodynamic flow alteration devices market in 2025. The regions covered in the hemodynamic flow alteration devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemodynamic flow alteration devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the hemodynamic flow alteration devices market by increasing the cost of imported medical-grade metals, polymers, guidewires, catheters, and precision-manufactured components used in embolic protection and chronic total occlusion devices. Hospitals and specialty care centers in North America and Europe are most affected due to reliance on imported interventional devices, while Asia-Pacific faces pricing pressure on export-oriented manufacturing. These tariffs are increasing device procurement costs and affecting procedure economics. However, they are also encouraging localized manufacturing, regional supplier development, and investment in domestic production capabilities for advanced cardiovascular devices.
The hemodynamic flow alteration devices market research report is one of a series of new reports that provides hemodynamic flow alteration devices market statistics, including hemodynamic flow alteration devices industry global market size, regional shares, competitors with a hemodynamic flow alteration devices market share, detailed hemodynamic flow alteration devices market segments, market trends and opportunities, and any further data you may need to thrive in the hemodynamic flow alteration devices industry. This hemodynamic flow alteration devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hemodynamic flow alteration devices are medical instruments designed to modify the dynamics of blood flow within the circulatory system. These devices are often utilized in procedures such as vascular surgery or heart condition treatments. They can influence factors such as the speed, direction, or resistance of blood flow to enhance circulation or reduce strain on vital organs.
The primary types of hemodynamic flow alteration devices include embolic protection devices and chronic total occlusion devices. An embolic protection device is specifically designed to capture and remove embolic material that may become dislodged during procedures such as angioplasty. This prevents the material from traveling to vital organs and causing blockages. These devices are used in various applications, including cardiovascular diseases, neurological disorders, renal conditions, and respiratory disorders, and are employed by several end users, including hospitals, clinics, ambulatory care centers, home care settings, and more.
The hemodynamic flow alteration devices market consists of sales of flow diverters, vascular stents, blood flow regulators, and monitoring tools. Values in and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hemodynamic flow alteration devices market size is expected to see strong growth in the next few years. It will grow to $1.3 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing adoption of precision medicine in vascular care, rising demand for minimally invasive cardiac procedures, expansion of neurovascular intervention capabilities, growing investment in advanced interventional cardiology devices, increasing focus on reducing procedural complications. Major trends in the forecast period include increasing adoption of advanced embolic protection technologies, rising use of minimally invasive flow alteration devices, growing integration of precision-guided cto devices, expansion of procedure-specific device designs, enhanced focus on patient-specific hemodynamic optimization.
The rising prevalence of cardiovascular diseases is expected to drive growth in the hemodynamic flow alteration devices market in the coming years. Cardiovascular disease (CVD) is a broad category of conditions affecting the heart and blood vessels. The increase in CVD prevalence is fueled by factors such as aging populations, poor dietary habits, sedentary lifestyles, and rising rates of conditions like hypertension and diabetes. Hemodynamic flow alteration devices are increasingly needed to manage and improve blood flow in patients with heart failure, hypertension, and arterial blockages. For example, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million individuals in the UK are currently affected by heart and circulatory diseases - 4 million men and 3.6 million women. This number is projected to rise by 1 million by 2030 and by 2 million more than current figures by 2040. Therefore, the growing prevalence of cardiovascular disease is driving the hemodynamic flow alteration devices market.
Major players in the hemodynamic flow alteration devices market are emphasizing technological innovations, such as hybrid polymer-metal flow-diverting stents, to enhance the safety, efficacy, and long-term outcomes of neurovascular interventions. Hybrid polymer-metal flow-diverting stents combine the mechanical strength of metal with the flexibility and biocompatibility of polymer, allowing controlled hemodynamic flow alteration, reduced thrombogenicity, and improved vessel healing in patients with brain aneurysms. For example, in June 2023, Fluid Biomed Inc., a Canada-based medical device company, launched REDIRECT, its first-in-human clinical trial, successfully implanting ReSolv, the world’s first hybrid polymer-metal neurovascular stent. The Phase 1 study demonstrated safe implantation with no adverse events at the 30-day follow-up, marking a milestone in brain aneurysm treatment by integrating advanced materials engineering with minimally invasive neurovascular therapy to improve patient outcomes.
In October 2024, Johnson & Johnson, a pharmaceutical company based in the US, acquired V-Wave Inc. for an undisclosed sum. This acquisition is intended to bolster Johnson & Johnson's position in the cardiovascular disease sector by adding V-Wave's groundbreaking Ventura interatrial shunt to its MedTech portfolio. V-Wave Inc., a US-based company, specializes in the development of hemodynamic flow alteration devices.
Major companies operating in the hemodynamic flow alteration devices market are Cardinal Health Inc., Abbott Laboratories, Medtronic plc, Siemens Healthcare GmbH, Becton Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., ZOLL Medical Corporation, Getinge AB, Lepu Medical Technology (Beijing) Co. Ltd., Abiomed Inc., LivaNova PLC, Cordis US Corp., Silk Road Medical Inc., Berlin Heart GmbH, CorWave SA, Jarvik Heart Inc., CARMAT SA.
North America was the largest region in the hemodynamic flow alteration devices market in 2025. The regions covered in the hemodynamic flow alteration devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemodynamic flow alteration devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the hemodynamic flow alteration devices market by increasing the cost of imported medical-grade metals, polymers, guidewires, catheters, and precision-manufactured components used in embolic protection and chronic total occlusion devices. Hospitals and specialty care centers in North America and Europe are most affected due to reliance on imported interventional devices, while Asia-Pacific faces pricing pressure on export-oriented manufacturing. These tariffs are increasing device procurement costs and affecting procedure economics. However, they are also encouraging localized manufacturing, regional supplier development, and investment in domestic production capabilities for advanced cardiovascular devices.
The hemodynamic flow alteration devices market research report is one of a series of new reports that provides hemodynamic flow alteration devices market statistics, including hemodynamic flow alteration devices industry global market size, regional shares, competitors with a hemodynamic flow alteration devices market share, detailed hemodynamic flow alteration devices market segments, market trends and opportunities, and any further data you may need to thrive in the hemodynamic flow alteration devices industry. This hemodynamic flow alteration devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hemodynamic flow alteration devices are medical instruments designed to modify the dynamics of blood flow within the circulatory system. These devices are often utilized in procedures such as vascular surgery or heart condition treatments. They can influence factors such as the speed, direction, or resistance of blood flow to enhance circulation or reduce strain on vital organs.
The primary types of hemodynamic flow alteration devices include embolic protection devices and chronic total occlusion devices. An embolic protection device is specifically designed to capture and remove embolic material that may become dislodged during procedures such as angioplasty. This prevents the material from traveling to vital organs and causing blockages. These devices are used in various applications, including cardiovascular diseases, neurological disorders, renal conditions, and respiratory disorders, and are employed by several end users, including hospitals, clinics, ambulatory care centers, home care settings, and more.
The hemodynamic flow alteration devices market consists of sales of flow diverters, vascular stents, blood flow regulators, and monitoring tools. Values in and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hemodynamic Flow Alteration Devices Market Characteristics
3. Hemodynamic Flow Alteration Devices Market Supply Chain Analysis
4. Global Hemodynamic Flow Alteration Devices Market Trends and Strategies
5. Hemodynamic Flow Alteration Devices Market Analysis of End Use Industries
7. Global Hemodynamic Flow Alteration Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hemodynamic Flow Alteration Devices Total Addressable Market (TAM) Analysis for the Market
9. Hemodynamic Flow Alteration Devices Market Segmentation
10. Hemodynamic Flow Alteration Devices Market Regional and Country Analysis
11. Asia-Pacific Hemodynamic Flow Alteration Devices Market
12. China Hemodynamic Flow Alteration Devices Market
13. India Hemodynamic Flow Alteration Devices Market
14. Japan Hemodynamic Flow Alteration Devices Market
15. Australia Hemodynamic Flow Alteration Devices Market
16. Indonesia Hemodynamic Flow Alteration Devices Market
17. South Korea Hemodynamic Flow Alteration Devices Market
18. Taiwan Hemodynamic Flow Alteration Devices Market
19. South East Asia Hemodynamic Flow Alteration Devices Market
20. Western Europe Hemodynamic Flow Alteration Devices Market
21. UK Hemodynamic Flow Alteration Devices Market
22. Germany Hemodynamic Flow Alteration Devices Market
23. France Hemodynamic Flow Alteration Devices Market
24. Italy Hemodynamic Flow Alteration Devices Market
25. Spain Hemodynamic Flow Alteration Devices Market
26. Eastern Europe Hemodynamic Flow Alteration Devices Market
27. Russia Hemodynamic Flow Alteration Devices Market
28. North America Hemodynamic Flow Alteration Devices Market
29. USA Hemodynamic Flow Alteration Devices Market
30. Canada Hemodynamic Flow Alteration Devices Market
31. South America Hemodynamic Flow Alteration Devices Market
32. Brazil Hemodynamic Flow Alteration Devices Market
33. Middle East Hemodynamic Flow Alteration Devices Market
34. Africa Hemodynamic Flow Alteration Devices Market
36. Hemodynamic Flow Alteration Devices Market Competitive Landscape and Company Profiles
37. Hemodynamic Flow Alteration Devices Market Other Major and Innovative Companies
40. Hemodynamic Flow Alteration Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Hemodynamic Flow Alteration Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hemodynamic flow alteration devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hemodynamic flow alteration devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemodynamic flow alteration devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Embolic Protection Device; Chronic Total Occlusion Device2) By Application: Cardiovascular Diseases; Neurological Disorders; Renal Disorders; Respiratory Disorders
3) By End User: Hospitals; Clinics; Ambulatory Care Centre; Home Care Setting; Other End Users
Subsegments:
1) By Embolic Protection Device: Distal Embolic Protection Devices; Proximal Embolic Protection Devices; Filter-Based Embolic Protection Devices; Balloon-Based Embolic Protection Devices; Mesh Or Cage-Based Embolic Protection Devices2) By Chronic Total Occlusion Device: Crossing Guidewires For CTO; CTO Balloon Catheters; CTO Microcatheters; Re-Entry Devices For CTO; CTO Support Catheters
Companies Mentioned: Cardinal Health Inc.; Abbott Laboratories; Medtronic plc; Siemens Healthcare GmbH; Becton Dickinson and Company; Stryker Corporation; Boston Scientific Corporation; Edwards Lifesciences Corporation; W. L. Gore & Associates Inc.; ZOLL Medical Corporation; Getinge AB; Lepu Medical Technology (Beijing) Co. Ltd.; Abiomed Inc.; LivaNova PLC; Cordis US Corp.; Silk Road Medical Inc.; Berlin Heart GmbH; CorWave SA; Jarvik Heart Inc.; CARMAT SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hemodynamic Flow Alteration Devices market report include:- Cardinal Health Inc.
- Abbott Laboratories
- Medtronic plc
- Siemens Healthcare GmbH
- Becton Dickinson and Company
- Stryker Corporation
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- W. L. Gore & Associates Inc.
- ZOLL Medical Corporation
- Getinge AB
- Lepu Medical Technology (Beijing) Co. Ltd.
- Abiomed Inc.
- LivaNova PLC
- Cordis US Corp.
- Silk Road Medical Inc.
- Berlin Heart GmbH
- CorWave SA
- Jarvik Heart Inc.
- CARMAT SA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.96 Billion |
| Forecasted Market Value ( USD | $ 1.3 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
